#US #NIH #Study Finds #Tecovirimat Was Safe but Did Not Improve #Mpox Resolution or #Pain, https://www.nih.gov/news-events/news-releases/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain

#Antiviral drug tecovirimat did not reduce time to lesion #resolution or have an effect on pain among adults with mild to moderate clade II mpox & a low risk of developing severe disease, according to an interim data analysis from international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

Source: Emerging Infectious Diseases Journal, https://wwwnc.cdc.gov/eid/article/30/11/24-1331_article

Abstract
We report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm3, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.

____

https://etidioh.wordpress.com/2024/10/21/mpox-hepatic-and-pulmonary-lesions-in-hiv-hepatitis-b-virus-co-infected-patient-france/

#abstract #antivirals #france #hepatitisB #HIVAIDS #mpox #research #tecovirimat

Source: US National Library of Medicine, https://pubmed.ncbi.nlm.nih.gov/39388389/

Abstract
The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.

____

https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/

#abstract #antivirals #california #drugsResistance #mpox #research #tecovirimat #USA

Notes from the Field: #Mpox #Cluster Caused by #Tecovirimat – #Resistant Monkeypox Virus – Five States, October 2023-February 2024

Source: US National Library of Medicine, AbstractThe antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners…

https://etidioh.wordpress.com/2024/10/11/notes-from-the-field-mpox-cluster-caused-by-tecovirimat-resistant-monkeypox-virus-five-states-october-2023-february-2024/

#Tecovirimat Use under Expanded Access to Treat #Mpox in #USA, 2022–2023, NEJM Evidence: https://evidence.nejm.org/doi/10.1056/EVIDoa2400189

Tecovirimat was used extensively. The returned EA-IND data suggest that life-threatening or protracted #infections occurred in persons who were severely immunocompromised. #SAEs were not commonly reported. The EA-IND data are not definitive; controlled clinical trial data are essential to elucidating if and how tecovirimat should be used.

#Mpox #outbreak — #tecovirimat #resistance, #management approaches, and #challenges in #HIV-endemic regions, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00591-7/fulltext?rss=yes

... while concentrating our efforts on responding to the current outbreak and gaining better insight into shifting MPXV biology in the human host, ensuring access to antivirals—particularly #ART—and comprehensive HIV care remains crucial.